Key statistics
On Friday, Arrowhead Pharmaceuticals Inc (0HI3:LSE) closed at 20.86, 4.85% above its 52-week low of 19.90, set on Sep 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 20.86 |
Low | 20.86 |
Bid | -- |
Offer | -- |
Previous close | 21.41 |
Average volume | 525.30 |
---|---|
Shares outstanding | 124.32m |
Free float | 118.76m |
P/E (TTM) | -- |
Market cap | 2.59bn USD |
EPS (TTM) | -4.65 USD |
Data delayed at least 20 minutes, as of Sep 20 2024 18:08 BST.
More ▼
Press releases
- Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
- Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
- Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
- Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
- Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
- Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
More ▼